The U.S. Food and Drug Administration (FDA) has recently released 14 previously unpublished drug rejection letters as part of its expanded transparency policy, marking the first such release after a 3‑month pause in the publication of complete response letters (CRLs). These letters had been issued to sponsors between 2020 and 2024 and were held back while the Department of Health and Human Services (HHS) reviewed the legal and procedural framework for public disclosure of rejection letters for unapproved drugs. The pause followed a citizen’s petition from a pharmaceutical company that raised concerns about patient privacy and commercial confidentiality, prompting HHS to develop a formal rule for disclosure. The 14 new letters, making up the latest tranche of CRLs added to the FDA’s public database, disclose common reasons for non‑approval, such as safety and efficacy concerns, manufacturing deficiencies, and bioequivalence issues, after redacting trade secrets and confidential information. Going forward, the FDA intends to publish CRLs in real time for both approved and withdrawn/unapproved applications, aligning with Executive Order No. 14303 to ensure greater transparency in regulatory decision‑making that affects public health and investment decisions in the biopharma sector.
Sources:
FDA publishes rejection letters sent to drugmakers, with a ...
FDA Embraces Radical Transparency by Publishing ...
FDA to publish drug rejection letters in transparency push
FDA Pauses Drug Rejection Letters Disclosure
US FDA publishes 200 complete response letters from archive in transparency drive
FDA Publishes Complete Response Letters for Unapproved Drug ...
F.D.A. Posts Collection of Letters Outlining Concerns About New Drugs
FDA Releases Complete Response Letters for Unapproved Drugs
FDA Will Share Rejection Letters Drugmakers Often Conceal
Unpacking the FDA transparency push on CRLs - Fierce Biotech